Expression of oestrogen receptor β and prognosis of colorectal cancer

被引:96
作者
Rudolph, A. [1 ]
Toth, C. [2 ,3 ]
Hoffmeister, M. [4 ]
Roth, W. [2 ]
Herpel, E. [2 ,3 ]
Jansen, L. [4 ]
Marx, A. [5 ]
Brenner, H. [4 ]
Chang-Claude, J. [1 ]
机构
[1] German Canc Res Ctr, Div Canc Epidemiol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Inst Pathol, Dept Gen Pathol, D-69120 Heidelberg, Germany
[3] Natl Ctr Tumor Dis NCT, NCT, Tissue Bank, D-69120 Heidelberg, Germany
[4] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, D-69120 Heidelberg, Germany
[5] Mannheim Univ Hosp, Inst Pathol, D-68167 Mannheim, Germany
关键词
colorectal cancer; prognosis; oestrogen receptor beta; nuclear receptor; sex steroids; prospective cohort; TISSUE MICROARRAY TECHNOLOGY; HUMAN BREAST-TISSUE; ER-BETA; COLON-CANCER; COX REGRESSION; SURVIVAL; ISOFORMS; IMMUNOHISTOCHEMISTRY; LIKELIHOOD; EPITHELIUM;
D O I
10.1038/bjc.2012.323
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Previous studies suggest that sex steroids influence colorectal cancer (CRC) carcinogenesis. The oestrogen receptor beta (ER beta) is the predominantly expressed ER in the colon and loss of ER beta in CRC has been associated with advanced cancer stages. METHODS: Information on vital status by the end of 2009 was obtained for 1262 CRC patients recruited between 2003 and 2007. The ER beta expression was immunohistochemically measured and associations of ER beta scores with overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS) were evaluated using Cox proportional hazard models adjusted for prognostic factors, such as tumour stage and second primary tumours. RESULTS: Of the 1101 tumour samples with successful measurement, 535 were ER beta negative (48.6%), 381 (34.6%) showed moderate and 185 (16.8%) showed high ER beta expression. Compared with high ER beta expression, lack of ER beta was associated with higher cancer stages as well as greater tumour extent. In multivariate analyses, ER beta negativity was associated with an increased hazard ratio for death (HR = 1.61, 95% CI 1.09-2.40, P = 0.02), death attributed to CRC (HR = 1.54, 95% CI 0.99-2.39, P = 0.06) as well as a poorer DFS (DFS HR = 1.64, 95% CI 1.23-3.36, P = 0.04). The associations were stronger in stage I-III patients (OS HR = 2.20, 95% CI 1.28-4.06, P = 0.007, DSS HR = 2.38, 95% CI 1.20-5.39, P = 0.02, respectively). CONCLUSIONS: Lack of ER beta expression is associated with advanced cancer stages and independently associated with poor survival. British Journal of Cancer (2012) 107, 831-839. doi: 10.1038/bjc.2012.323 www.bjcancer.com Published online 24 July 2012 (C) 2012 Cancer Research UK
引用
收藏
页码:831 / 839
页数:9
相关论文
共 39 条
  • [1] Dietary-induced ERβ upregulation counteracts intestinal neoplasia development in intact male ApcMin/+ mice
    Barone, Michele
    Tanzi, Sabina
    Lofano, Katia
    Scavo, Maria Principia
    Pricci, Maria
    Demarinis, Lucia
    Papagni, Samanta
    Guido, Raffaella
    Maiorano, Eugenio
    Ingravallo, Giuseppe
    Comelli, Maria Cristina
    Francavilla, Antonio
    Di Leo, Alfredo
    [J]. CARCINOGENESIS, 2010, 31 (02) : 269 - 274
  • [2] Protection From Colorectal Cancer After Colonoscopy A Population-Based, Case-Control Study
    Brenner, Hermann
    Chang-Claude, Jenny
    Seiler, Christoph M.
    Rickert, Alexander
    Hoffmeister, Michael
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 22 - U156
  • [3] Campbell-Thompson M, 2001, CANCER RES, V61, P632
  • [4] A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERβ in archival formalin-fixed paraffin embedded human breast tissue
    Carder, PJ
    Murphy, CE
    Dervan, P
    Kennedy, M
    McCann, A
    Saunders, PTK
    Shaaban, AM
    Foster, CS
    Witton, CJ
    Bartlett, JMS
    Walker, RA
    Speirs, V
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 92 (03) : 287 - 293
  • [5] Several methods to assess improvement in risk prediction models: Extension to survival analysis
    Chambless, Lloyd E.
    Cummiskey, Christopher P.
    Cui, Gang
    [J]. STATISTICS IN MEDICINE, 2011, 30 (01) : 22 - 38
  • [6] Aspirin Use and Survival After Diagnosis of Colorectal Cancer
    Chan, Andrew T.
    Ogino, Shuji
    Fuchs, Charles S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (06): : 649 - 659
  • [7] Preventive therapy for breast cancer: a consensus statement
    Cuzick, Jack
    DeCensi, Andrea
    Arun, Banu
    Brown, Powel H.
    Castiglione, Monica
    Dunn, Barbara
    Forbes, John F.
    Glaus, Agnes
    Howell, Anthony
    von Minckwitz, Gunter
    Vogel, Victor
    Zwierzina, Heinz
    [J]. LANCET ONCOLOGY, 2011, 12 (05) : 496 - 503
  • [8] Systematic Review: Anti-Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer
    Dahabreh, Issa J.
    Terasawa, Teruhiko
    Castaldi, Peter J.
    Trikalinos, Thomas A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 37 - U180
  • [9] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
    Davies, C.
    Godwin, J.
    Gray, R.
    Clarke, M.
    Darby, S.
    McGale, P.
    Wang, Y. C.
    Peto, R.
    Pan, H. C.
    Cutter, D.
    Taylor, C.
    Ingle, J.
    [J]. LANCET, 2011, 378 (9793) : 771 - 784
  • [10] Potential Value of Estrogen Receptor Beta Expression in Colorectal Carcinoma: Interaction with Apoptotic Index
    Hosam Ghazy Elbanna
    Mohamed Awad Ebrahim
    Amr Medhat Abbas
    Khaled Zalata
    Maha Abo Hashim
    [J]. Journal of Gastrointestinal Cancer, 2012, 43 (1) : 56 - 62